Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-hodgkin lymphomas

Luis F. Porrata; David J. Inwards; Ivana N. Micallef; Patrick B. Johnston; Stephen M. Ansell; William J. Hogan; Svetomir N. Markovic

doi:10.1155/2010/914945

Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-hodgkin lymphomas

Luis F. Porrata, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Stephen M. Ansell, William J. Hogan, Svetomir N. Markovic

Hematology

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Natural killer cells at day 15 (NK-15), after autologous peripheral blood hematopoietic stem cell transplantation (APHSCT), is a prognostic factor for overall survival (OS) and progression-free survival (PFS) in non-Hodgkin lymphoma (NHL). The potential role of the immunologic (homeostatic) environment affecting NK-15 recovery and survival post-APHSCT has not been fully studied. Therefore, we evaluate prospectively the cytokine profile in 50 NHL patients treated with APHSCT. Patients with an interleukin-15 (IL-15)≥76.5 pg/mL at day 15 post-APHSCT experienced superior OS and PFS compared with those who did not; median OS; not reached versus 19.2 months, P<.002; and median PFS; not reached versus 6.8 months, P<.002, respectively. IL-15 was found to correlate with (r_s =0.7, P<.0001) NK-15. Multivariate analysis showed only NK-15 as a prognostic factor for survival, suggesting that the survival benefit observed by IL-15 is most likely mediated by enhanced NK cell recovery post-APHSCT.

Original language	English (US)
Article number	914945
Journal	Clinical and Developmental Immunology
Volume	2010
DOIs	https://doi.org/10.1155/2010/914945
State	Published - 2010

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1155/2010/914945

Cite this

Porrata, L. F., Inwards, D. J., Micallef, I. N., Johnston, P. B., Ansell, S. M., Hogan, W. J., & Markovic, S. N. (2010). Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-hodgkin lymphomas. Clinical and Developmental Immunology, 2010, Article 914945. https://doi.org/10.1155/2010/914945

@article{7616c42f9b5c44d581396a6a2d982e5a,

title = "Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-hodgkin lymphomas",

abstract = "Natural killer cells at day 15 (NK-15), after autologous peripheral blood hematopoietic stem cell transplantation (APHSCT), is a prognostic factor for overall survival (OS) and progression-free survival (PFS) in non-Hodgkin lymphoma (NHL). The potential role of the immunologic (homeostatic) environment affecting NK-15 recovery and survival post-APHSCT has not been fully studied. Therefore, we evaluate prospectively the cytokine profile in 50 NHL patients treated with APHSCT. Patients with an interleukin-15 (IL-15)≥76.5 pg/mL at day 15 post-APHSCT experienced superior OS and PFS compared with those who did not; median OS; not reached versus 19.2 months, P<.002; and median PFS; not reached versus 6.8 months, P<.002, respectively. IL-15 was found to correlate with (rs =0.7, P<.0001) NK-15. Multivariate analysis showed only NK-15 as a prognostic factor for survival, suggesting that the survival benefit observed by IL-15 is most likely mediated by enhanced NK cell recovery post-APHSCT.",

author = "Porrata, {Luis F.} and Inwards, {David J.} and Micallef, {Ivana N.} and Johnston, {Patrick B.} and Ansell, {Stephen M.} and Hogan, {William J.} and Markovic, {Svetomir N.}",

year = "2010",

doi = "10.1155/2010/914945",

language = "English (US)",

volume = "2010",

journal = "Clinical and Developmental Immunology",

issn = "1740-2522",

publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-hodgkin lymphomas

AU - Porrata, Luis F.

AU - Inwards, David J.

AU - Micallef, Ivana N.

AU - Johnston, Patrick B.

AU - Ansell, Stephen M.

AU - Hogan, William J.

AU - Markovic, Svetomir N.

PY - 2010

Y1 - 2010

N2 - Natural killer cells at day 15 (NK-15), after autologous peripheral blood hematopoietic stem cell transplantation (APHSCT), is a prognostic factor for overall survival (OS) and progression-free survival (PFS) in non-Hodgkin lymphoma (NHL). The potential role of the immunologic (homeostatic) environment affecting NK-15 recovery and survival post-APHSCT has not been fully studied. Therefore, we evaluate prospectively the cytokine profile in 50 NHL patients treated with APHSCT. Patients with an interleukin-15 (IL-15)≥76.5 pg/mL at day 15 post-APHSCT experienced superior OS and PFS compared with those who did not; median OS; not reached versus 19.2 months, P<.002; and median PFS; not reached versus 6.8 months, P<.002, respectively. IL-15 was found to correlate with (rs =0.7, P<.0001) NK-15. Multivariate analysis showed only NK-15 as a prognostic factor for survival, suggesting that the survival benefit observed by IL-15 is most likely mediated by enhanced NK cell recovery post-APHSCT.

AB - Natural killer cells at day 15 (NK-15), after autologous peripheral blood hematopoietic stem cell transplantation (APHSCT), is a prognostic factor for overall survival (OS) and progression-free survival (PFS) in non-Hodgkin lymphoma (NHL). The potential role of the immunologic (homeostatic) environment affecting NK-15 recovery and survival post-APHSCT has not been fully studied. Therefore, we evaluate prospectively the cytokine profile in 50 NHL patients treated with APHSCT. Patients with an interleukin-15 (IL-15)≥76.5 pg/mL at day 15 post-APHSCT experienced superior OS and PFS compared with those who did not; median OS; not reached versus 19.2 months, P<.002; and median PFS; not reached versus 6.8 months, P<.002, respectively. IL-15 was found to correlate with (rs =0.7, P<.0001) NK-15. Multivariate analysis showed only NK-15 as a prognostic factor for survival, suggesting that the survival benefit observed by IL-15 is most likely mediated by enhanced NK cell recovery post-APHSCT.

UR - http://www.scopus.com/inward/record.url?scp=77952479517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952479517&partnerID=8YFLogxK

U2 - 10.1155/2010/914945

DO - 10.1155/2010/914945

M3 - Article

C2 - 20414345

AN - SCOPUS:77952479517

SN - 1740-2522

VL - 2010

JO - Clinical and Developmental Immunology

JF - Clinical and Developmental Immunology

M1 - 914945

ER -

Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-hodgkin lymphomas

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this